AOD-9604 (5 mg)
Table of Contents
Quickstart Highlights
AOD-9604 dosage protocol is designed to support targeted fat loss and metabolic improvements through daily subcutaneous injections.
- Typical starting dose between 300–400 mcg per day
- Once-daily injection schedule (can split doses in advanced protocol)
- Gradual dose titration to manage tolerance and optimize results
- Reconstitute with ~3 mL bacteriostatic water (≈1.67 mg/mL solution)
- Store lyophilized peptide frozen; refrigerate solution after mixing
Dosing & Reconstitution Guide
Educational guide for reconstitution and dosing protocol
Standard / Gradual Approach (3 mL = 1.67 mg/mL)
| PHASE | DAILY DOSE | UNITS (PER INJECTION) |
|---|---|---|
| Weeks 1–4 | 300 mcg (0.3 mg) | 18 units (0.18 mL) |
| Weeks 5–12 | 400 mcg (0.4 mg) | 24 units (0.24 mL) |
| Weeks 13–16 (Optional) | 400–500 mcg (0.4–0.5 mg) | 30 units (0.30 mL) at 500 mcg |
Ideal for most users starting at lower doses (up to ~400 mcg daily). Reconstitute the 5 mg vial with 3.0 mL bacteriostatic water for a final concentration of ~1.67 mg/mL. Each 100-unit insulin syringe unit corresponds to ~16.7 mcg of peptide.
- Draw 3.0 mL of bacteriostatic water into a sterile syringe.
- Inject the water slowly along the vial wall to minimize foam.
- Gently swirl the vial until the peptide fully dissolves (do not shake).
- Store the reconstituted solution in the refrigerator at 2–8 °C (36–46°F), protected from light.
Advanced / Aggressive Approach (3 mL = 1.67 mg/mL)
| PHASE | DAILY DOSE | UNITS (PER INJECTION) |
|---|---|---|
| Weeks 1–4 | 300 mcg (0.3 mg) once daily | 18 units (0.18 mL) |
| Weeks 5–12 | 500 mcg total (split as 250 mcg AM + 250 mcg PM) | 15 units each (0.15 mL each) |
| Weeks 13–16 (Optional) | 500 mcg total (250 mcg twice daily) | 15 units each (0.15 mL each) |
For higher-dose regimens or plateaued results. Reconstitute with 3.0 mL for 1.67 mg/mL. This yields 15 units per 250 mcg injection (administer twice daily to reach 500 mcg total). Splitting doses can help maintain steady peptide levels and may enhance fat oxidation.
- Draw 3.0 mL of bacteriostatic water into a sterile syringe.
- Inject slowly to prevent foaming.
- Gently roll/swirl the vial to dissolve the peptide.
- Store the reconstituted solution refrigerated at 2–8 °C, and use within 28 days.
Note: This guide is for educational purposes only. Always consult a healthcare professional before starting any new therapy.
Protocol Overview
A concise summary of this fat-loss regimen.
- Goal: Promote targeted fat loss and metabolic support
- Schedule: Daily subcutaneous injections for 8–12 weeks
- Dose Range: Start at ~300 mcg/day, titrate up to 500 mcg/day if needed
- Reconstitution: Use ~3 mL bacteriostatic water (≈1.67 mg/mL)
- Storage: Freeze vials (−20°C); refrigerate reconstituted solution (2–8°C):contentReference[oaicite:1]{index=1}
Dosing Protocol
Suggested daily injection approach with gradual titration.
- Start Dose: 300 mcg once daily (fasted or pre-workout)
- Titration: Increase by 100 mcg every 2–4 weeks as tolerated
- Frequency: Once daily (advanced: consider twice daily split dosing)
- Cycle Length: 8–12 weeks (extend with breaks if needed)
- Maximum Dose: Up to 500 mcg daily (over 1 mg shows no added benefit)
Storage Instructions
Proper storage ensures peptide integrity:contentReference[oaicite:3]{index=3}.
- Lyophilized: Freeze at −20°C or colder:contentReference[oaicite:4]{index=4}
- Reconstituted:Reconstituted: Refrigerate at 2–8°C (36–46°F)
- Avoid repeated freeze-thaw cycles of the solution:contentReference[oaicite:5]{index=5}
Suppilies Needed
Ensure you have these on hand for an 8–16 week cycle.
- Peptide Vials:
• 8 wks ≈ 4 vials
• 12 wks ≈ 6 vials
• 16 wks ≈ 8 vials
(Approximate; higher doses or longer cycles require more)
- Insulin Syringes:
• 8 wks ≈ 56 (50-unit)
• 12 wks ≈ 84
• 16 wks ≈ 112
- Bacteriostatic Water: 3× 10 mL vials
- Alcohol Swabs: 1 box
Important Notes
Practical tips to enhance safety and efficacy.
- Always use new, sterile insulin syringes & rotate injection sites (abdomen, thigh, etc.).
- Maintain consistent dosing time each day for best results.
- Monitor for any adverse reactions; consult healthcare provider if needed.
- Track your progress and adjust dose cautiously under guidance.
How This Works
AOD-9604 is derived from the tail end of human growth hormone, focusing on its fat-burning effects.
- Fat Metabolism: Specifically activates lipolysis in adipose tissue, helping mobilize stored fat.
- Inhibits Fat Storage: Suppresses new fat formation (lipogenesis) in stubborn areas.
- No IGF-1 / Glucose Impact: Unlike full HGH, it does not raise IGF-1 or impair glucose tolerance.
Potential Benefits & Side Effects
AOD-9604 may help reduce fat while preserving muscle, with a generally mild side effect profile.
- Enhances targeted fat loss (especially abdominal fat) in clinical studies.
- Preserves lean muscle and normal metabolism (no IGF-1 elevation).
- May improve metabolic markers (some trials showed better cholesterol and glucose tolerance).
- Generally well-tolerated; human trials reported safety similar to placebo with no serious adverse events.
- Possible mild effects: injection-site irritation, transient fatigue or nausea in some users.
Lifestyle Factors
Complementary strategies for maximum benefit.
- Follow a nutrient-rich, calorically appropriate diet (high protein helps preserve muscle).
- Incorporate regular exercise (especially cardio) to complement fat loss.
- Ensure adequate sleep and stress management to support metabolism.
Injection Technique
Simple guidelines for safe daily injections.
- Clean the vial stopper and your skin with an alcohol swab.
- Pinch up a fold of subcutaneous fat and insert the needle at a 45–90° angle.
- Inject the solution slowly and remove the needle gently.
- Rotate injection sites each day to avoid tissue irritation.
Recommended Source
We recommend GoAlphaLabs Peptides for high-purity AOD-9604 (5 mg).
Why GoAlphaLabs Peptides?
- Verifies ≥99% purity through independent lab testing
- Trusted by researchers for reliable, consistent peptide quality
- Adheres to strict GMP manufacturing standards
Important Note: This guide is for educational purposes only. Always consult a qualified healthcare provider before starting or modifying any therapy.
References
| Source | Link |
|---|---|
| PubMed Central (PMC) - Misra et al., review of obesity pharmacotherapy | View Source |
| Journal of Endocrinology & Metabolism - Moré et al., safety & metabolism of AOD-9604 | View Source |
| Journal of Endocrinology & Metabolism - Stier et al., clinical safety and tolerability of AOD-9604 | View Source |
| Nature Reviews: Endocrinology - Misra, “Obesity Pharmacotherapy: Current Perspectives and Future Directions” | View Source |
| News-Medical - Obesity drug codenamed AOD9604 highly successful in trials” | View Source |
| BioSpace (PR Newswire) - “First 100 subjects complete Phase 2B trial of AOD9604” | View Source |
| Annals of Clinical and Laboratory Science - Kwon et al., AOD-9604 injections in osteoarthritis model | View Source |
| Sigma-Aldrich (MilliporeSigma) - Handling and storage guidelines for peptides | View Source |